[1] Hayashi PH, Lucena MI, Fontana RJ, et al. A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology, 2022,76:18-31.
[2] 于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南. 实用肝脏病杂志, 2017,20:257-274.
[3] Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci, 2015,17.
[4] Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology, 1997,26:664-9.
[5] García-Cortés M, Lucena MI, Pachkoria K, et al. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther, 2008,27:780-9.
[6] Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology, 2010,51:2117-26.
[7] Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol, 1990,11:272-6.
[8] Danan G. Causality assessment of drug-induced liver injury. Hepatology Working Group. J Hepatol, 1988,7:132-6.
[9] Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol, 1993,46:1323-30.
[10] Teschke R. Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019. Front Pharmacol, 2019,10:730.
[11] Wang R, Qi X, Yoshida EM, et al. Clinical characteristics and outcomes of traditional Chinese medicine-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol, 2018,12:425-434.
[12] 吴丽. 改良的RUCAM量表在药物性肝损伤临床诊断中的应用分析: 华中科技大学, 2019.
[13] 何婷婷. 187例中草药及其制剂导致肝损伤病例临床研究, In 2017年第五次世界中西医结合大会, 中国广东广州, 2017.
[14] 孙静, 李家斌, 叶英. 基于RUCAM量表的205例药物性肝损伤患者临床特点分析. 安徽医学, 2016,37:272-275.
[15] Danjuma MI, Almasri H, Alshokri S, et al. Avoidability of drug-induced liver injury (DILI) in an elderly hospital cohort with cases assessed for causality by the updated RUCAM score. BMC Geriatr, 2020,20:346.
[16] Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol, 1993,46:1331-6.
[17] Teschke R, Méndez-Sánchez N, Eickhoff A. Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method. Int J Mol Sci, 2022,23.
[18] Aiso M, Takikawa H, Tsuji K, et al. Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan. Hepatol Res, 2019,49:105-110.
[19] Rathi C, Pipaliya N, Patel R, et al. Drug Induced Liver Injury at a Tertiary Hospital in India: Etiology, Clinical Features and Predictors of Mortality. Ann Hepatol, 2017,16:442-450.[20] 于乐成, 陈成伟. 在药物性肝损伤诊断中RUCAM为何具有持久的生命力? 肝脏, 2018,23:371-375.
[21] Hayashi PH, Lucena MI, Fontana RJ. RECAM: A New and Improved, Computerized Causality Assessment Tool for DILI Diagnosis. Am J Gastroenterol, 2022,117:1387-1389.
[22] 赖荣陶, 陈成伟, 阳文新, et al. 药物性肝损伤因果关系评估量表:RECAM将取代RUCAM? 肝脏, 2022,27:725-729.
[23] Raschi E, Caraceni P. Letter to the editor: RECAM for the diagnosis of DILI-Is it time to incorporate additional pharmacological criteria? Hepatology, 2022,76:E25-e26.
[24] Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. Hepatology, 2016,63:590-603.
[25] Lewis JH. Digitizing DILI: Who can? RUCAM? RECAM? Hepatology, 2022,76:3-5.
[26] Woo SM, Alhaqqan DM, Gildea DT, et al. Highlights of the drug-induced liver injury literature for 2021. Expert Rev Gastroenterol Hepatol, 2022,16:767-785.
[27] Teschke R, Danan G. Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis. Medicines (Basel), 2020, 7. |
